Skip to content
A5860Assembly2021-2022 SessionSame asS3081

Stop Medicine Price Gouging

Official title

“Relates to price gouging of medicine”

Sponsor Karines ReyesAD-87+4 co-sponsorsAffects Legal
Status
Assembly Floor Calendar
Impact
7/10
Significant
Passage
0%

Bill progress

Vetoed via S3081

What's happening

This bill prohibits price gouging of medicines during FDA-declared shortages, setting penalties for excessive pricing and enabling legal action.

Why it matters

  1. Protects consumers from exploitative pricing when medicines are scarce. , helping ensure that critical drugs remain financially accessible during periods of shortage, which can be life-saving for individuals who depend on them.

  2. Establishes clear legal standards for what constitutes "unconscionably excessive" pricing. , giving courts explicit criteria (such as price disparities before and after shortages, or unfair leverage) to determine when a seller has violated the law.

  3. Empowers the state attorney general to take swift legal action. , including seeking court orders to stop illegal pricing and imposing substantial civil penalties—this increases the likelihood of enforcement and deterrence against would-be violators.

  4. Provides potential restitution for affected buyers. , meaning individuals or entities harmed by excessive drug prices during shortages could receive compensation, offering a direct remedy and further discouraging price gouging.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Stop Medicine Price Gouging

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Karines Reyes

Assembly Member · Assembly District 87

History

  1. Substituted by S3081B
  2. Rules report cal.528
  3. Reported
  4. Reported referred to rules
  5. Print number 5860b
  6. Amend and recommit to codes
  7. Reported referred to codes
  8. Referred to consumer affairs and protection
  9. Print number 5860a
  10. Amend and recommit to consumer affairs and protection
  11. Referred to consumer affairs and protection

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S3081Senate

Stop Medicine Price Gouging

Vetoed · Sponsor Julia Salazar

Impact 7 · SignificantVetoed

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5860--B

2021-2022 Regular Sessions

IN ASSEMBLY

March 1, 2021

Introduced by M. of A. REYES, WILLIAMS -- read once and referred to the Committee on Consumer Affairs and Protection -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- recommitted to the Committee on Consumer Affairs and Protection in accordance with Assembly Rule 3, sec. 2 -- reported and referred to the Committee on Codes -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the general business law, in relation to the price gouging of medicine

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The general business law is amended by adding a new section 396-rrr to read as follows:

§ 396-rrr. Price gouging of medicine. 1. For the purposes of this section, "drug subject to a shortage" shall mean any drug or medical product intended for human use publicly reported as being subject to a shortage by the U.S. food and drug administration on its website, provided, however, that a drug or medical product shall only be considered a "drug subject to a shortage" during the period of time that such drug or medical product is listed as being subject to a shortage on such website.

2. No manufacturer, supplier, wholesaler, distributor or retail seller of any drug subject to a shortage shall sell or offer to sell any such drug subject to a shortage for an amount which represents an unconscionably excessive price.

3. Whether a price is unconscionably excessive is a question of law for the court.

(a) The court's determination that a violation of this section has occurred shall be based on any of the following factors:

(i) that the amount of the excess in price is unconscionably extreme;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD06581-04-2

(ii) that there was an exercise of unfair leverage or unconscionable means; or

(iii) a combination of both factors in subparagraphs (i) and (ii) of this paragraph.

(b) In any proceeding commenced pursuant to subdivision four of this section, prima facie proof that a violation of this section has occurred shall include evidence that:

(i) the amount charged represents a gross disparity between the price of the drug subject to a shortage which was the subject of the transaction and their value measured by the price at which such drug was sold or offered for sale by the defendant in the usual course of business immediately prior to the onset of the shortage; or

(ii) the amount charged grossly exceeded the price at which the same or similar drug subject to a shortage was readily obtainable by other purchasers in the trade area.

(c) A defendant may rebut a prima facie case with evidence that:

(i) the increase in the amount charged preserves the margin of profit that the defendant received for the same drug subject to a shortage prior to the onset of the shortage; or

(ii) additional costs not within the control of the defendant were imposed on the defendant for the drug subject to a shortage.

4. Where a violation of this section is alleged to have occurred, the attorney general may apply in the name of the People of the State of New York to the supreme court within the judicial district in which such violation is alleged to have occurred, on notice of five days, for an order enjoining or restraining commission or continuance of the alleged unlawful acts. In any such proceeding, the court shall impose a civil penalty in an amount not to exceed twenty-five thousand dollars per violation or three times the gross receipts for the relevant drug subject to the shortage, whichever is greater, and where appropriate, order restitution to aggrieved parties.

§ 2. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.